http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-102012019046-B1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_240e1cd00a69820e67a50d867333fd02
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C255-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-277
filingDate 2012-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcde1ffe4b08e593d03ede0e3bf4b26a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1a3ad780abc885539b0a2205114dc28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb7870c1a62f13e0c331f1800254d25e
publicationDate 2020-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber BR-102012019046-B1
titleOfInvention process of obtaining verapamil enantiomers in a conventional and unconventional simulated mobile bed
abstract process of obtaining verapamil enantiomers in a conventional and unconventional simulated mobile bed. the present invention deals with a process of obtaining enantiomers of the drug verapamil by means of continuous chromatography in conventional and unconventional simulated moving bed. if, on the one hand, the enantiomers are currently separated only on an analytical scale, in a batch process, with a strictly pharmaceutical view, on the other hand, the present invention allows for an increase in scale in the production of the drug's enantiomers, making it possible to add commercial value to the product and the realization clinical trials in scientific research in the field with separate enantiomers. in addition, the commercialization of the drug, enantiomerically pure, will meet the requirements imposed by health regulatory agencies, with regard to the characterization of the pharmacokinetic and pharmacodynamic profiles of individual enantiomers. the present invention, using two different simulated moving bed techniques, allows to obtain the enantiomers with low operating cost and desirable productivity in a relatively short time scale when compared to the chromatographic process operated in batch mode, currently employed. it also makes it possible to reduce solvent consumption and increase the recovery of enantiomers per unit of chiral stationary phase mass used.
priorityDate 2012-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2520
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419513958
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538410
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3027979
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8021
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419585083
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505994
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419487106
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7150
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID702
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419520471
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8058
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4594
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3776
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506849
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419522973
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID154342
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID416223349

Total number of triples: 32.